Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial
- 9 September 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (12) , 11239-11247
Abstract
Aims: To evaluate whether intravitreal ranibizumab (IVR) frequency is associated with longitudinal renal markers in diabetic macular oedema (DMO) and whether the expected systemic renal and haematological effects of SGLT2 inhibition are reproduced. Materials and Methods: In this post hoc sub‐analysis of the prospective COMET randomised controlled trial, 53 participants were analysed. The estimated glomerular filtration rate (eGFR), haematocrit (Hct), and urinary albumin‐to‐creatinine ratio (UACR) were assessed over 48 weeks using linear mixed‐effects models with the treatment group, week, group‐by‐week interaction, and cumulative IVR as fixed effects. Results: Baseline eGFR was preserved (72.2 ± 18.5 mL/min/1.73 m 2 ) despite common albuminuria (median UACR 50.6 mg/gCr); mean cumulative IVR at week 48 was 7.00 ± 4.42. Cumulative IVR was not significantly associated with eGFR (−0.22 mL/min/1.73 m 2 per injection; 95% CI −0.59 to 0.15; p = 0.25), ln(UACR), or Hct. The SGLT2 inhibitor reproduced an early eGFR dip and Hct rise. Conclusions: No statistically significant exposure‐response association was detected between cumulative IVR and renal markers within the COMET trial cohort and dosing range. Because all participants received IVR and the sample size was modest, small cumulative renal effects cannot be excluded. Trial Registration: University Hospital Medical Information Network Center (UMIN000057674); Japan Registry of Clinical Trials (jRCTs031180210, parent COMET trial)Keywords
This publication has 27 references indexed in Scilit:
- Longitudinal renal function changes during real-world anti-vascular endothelial growth factor therapy for diabetic macular edema in JapanJapanese Journal of Ophthalmology, 2025
- Long-Term Change in Renal Function After Intravitreal Anti-VEGF Treatment for Diabetic Macular Edema: A 2-Year Retrospective Cohort StudyOphthalmology and Therapy, 2023
- Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled TrialDiabetes Therapy, 2020
- Intravitreal anti-VEGF agents and cardiovascular riskInternal and Emergency Medicine, 2019
- Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidenceKidney International, 2019
- Association of Abnormal Renal Profiles and Proliferative Diabetic Retinopathy and Diabetic Macular Edema in an Asian Population With Type 2 DiabetesJAMA Ophthalmology, 2018
- Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic RetinopathyJAMA, 2015
- The REVEAL StudyOphthalmology, 2015
- Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular EdemaOphthalmology, 2014
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysisJournal of the American Society of Hypertension, 2014